Lentinan with S-i and paclitaxel for gastric cancer chemotherapy improve patient quality of life

Hepato-Gastroenterology

Volumn 56, Issue 90, 2009, Pages 547-550

  Kataoka, Hiromi ^a   Shimura, Takaya ^a   Mizoshita, Tsutomu ^a   Kubota, Eiji ^a   Moni, Yoshinori ^a   Mizushima, Takashi ^a   Wada, Tsuneya ^a   Ogasawara, Naotaka ^a   Tanida, Satoshi ^a   Sasaki, Makoto ^a   Togawa, Shozo ^b   Sano, Hitoshi ^b   Hirata, Yoshikazu ^a,c   Ikai, Masahiro ^c   Mochizuki, Hisato ^d   Seno, Kyoji ^d   Itoh, Sachie ^e   Kawai, Takashi ^e   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Gifu Prefectural Tajimi Hospital   (Japan)

^c Kasugai Municipal Hospital   (Japan)

^d Asalti Rosai Hospital   (Japan)

^e Jyousai municipal Hospital   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Quality of life; S i Paciftaxel

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; LENTINAN; PACLITAXEL; SOLUBLE INTERLEUKIN 2 RECEPTOR; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TEGAFUR; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BINDING; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; FLOW CYTOMETRY; FLUSHING; HUMAN; HYPERBILIRUBINEMIA; INOPERABLE CANCER; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG FIBROSIS; MONOCYTE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH CANCER; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; ANALYSIS OF VARIANCE; BLOOD; DRUG COMBINATION; FEMALE; MALE; PATHOLOGY; PROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; HUMANS; LENTINAN; MALE; OXONIC ACID; PACLITAXEL; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67649197058     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chiliara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F: Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature 1969; 222:687-688.
2. Taguchi T: Clinical efficacy of lentinan on patienta with stomach cancer: end point results of a four-year follow-up survey. Cancer Detect Prey Suppl 1987; 1:333-349.
3. Abel G, Szollosi J, Chihara G, Fachet J: Effect of lenti nan and mannan on phagocytosis of fluorescent latex microbeads by mouse peritoneal macrophages: a flow cytometric study. Int J Immunopharmacol 1989;1 1:615-621.
4. Fujimoto K, Tomonaga M, Goto S: A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan. Anticancer Res 2006; 26:40 15-4018.
5. Nakano H, Namatanie K, Nemoto H, et al: A multi-insti tutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quali ty of life. Kanagawa Lentinan Research Group. Hepatogas troenterology 1999; 46:2662-2668.
6. Okuyama K, Isono K, Juan 1K, et al: Evaluation of treatment for gastric cancer with liver metastasis. Cancer 1985;55:2498-2505.
7. Kupfahl C, Geginat G, Hof H: Lentinan has a stimulatory effect on innate and adaptive immunity against murine lAs teria monocytogenes infection. Int Immunopharmacol 2006; 6:686-696.
8. Sullivan R, Smith JE, Rowan NJ: Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med 2006; 49:159-170.
9. Takeshita K, Hayashi S, Tani M, et al: Monocyte function associated with intermittent lentinan therapy after resection of gastric cancer. Surg Oncol 1996; 5:23-28.
10. Suga Y MM, Suga T: Analysis of binding of beta-glucan to mouse peripheral blood leukocytes. Biotherapy 2005; 19:197-203.
11. Hamuro J: Anticancer immunotherapy with perorally effec tive lentinan. Gan To Kagaku Ryoho 2005; 32:1209-1215.
12. Suzuki M, Takatsuki F, Maeda YY, Hamuro J, Chihara G: Antitumor and immunological activity of lentinan in com parison with LPS. Int J Immunopharmacol 1994; 16:463-468.
13. Gelin J, Moldawer LL, Lonnroth C, et al: Role of endoge nous tumor necrosis factor alpha and interleukin 1 for exper imental tumor growth and the development of cancer cachexia. Cancer Res 1991; 51:415-421.
14. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM: Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003; 197:1107-1117.
15. Herre J, Willment JA, Gordon 5, Brown GD: The role of Dectin-1 in antifungal immualty. Crit Rev Immunol 2004; 24:193-203.
16. Brown GD, Taylor PR, Reid DM, et al: Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 2002; 196:407-412.
17. Herre J, Gordon 5, Brown GD: Dectin-1 and its role in the recognition of beta-glucans by macrophages. Mal Immunol 2004; 40:869-876.
18. Cheung NK, Modak 5, Vickers A, Knuckles B: Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 2002; 51:557-564.
19. Tsikitis YE, Albina JE, Reichner JS: Beta-glucan affects leukocyte navigation in a complex chemotactic gradient. Surgery 2004; 136:384-389.
20. Mushiake H, Tsunoda T, Nukatsuka M, et al: Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo. Cancer Immunol Immunother 2005; 54:120-128.
21. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
22. Kurihara M, Shiniizu H, Tsuhoi K, et al: Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 1999; 8:355-363.
23. Kishida E, Sone Y, Shibata S, Misaki A: Preparation and immunochemical characterization of antibody to branched beta-(1,3)-D-glucan of Valvariella volvasea, and its use in studies of antitumor actions. Agric Biol Chem 1989; 53:1849- 1859.
24. Nimura H, Mitsumori N, Tsukagoshi S, et al: Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer. Gan To Kagaku Ryoho 2003; 30:1289-1296.
25. Nimura H, Mitsumori N, Takahashi N, et al: (S-i combined with lentinan in patients with unresectable or recurrent gastric cancer). Gan To Kagaku Ryoho 2006; 33 Suppl 1:106-109.
26. Kimura Y, lijima S, Kato T, et al: Usefulness of TS-1 and lentinan combination immunochemotherapy in advanced or recurrent gastric cancer--pilot study aiming at a randomized trial. Gan To Kagaku Ryoho 2003; 30:1125-1130.
27. Gotoh M, Kawabe 5, Takiuchi H: (S-i combined with weekly paditaxel in patients with advanced gastric cancer). Gan To Kagaku Ryoho 2006;33 Suppl 1:91-94.
28. Isoda N, Eguchi Y, Nukaya H, et al: Safety and availability of functional food containing immune adjuvant lentinan (beta-1,3-glucan), in patients with unresectable and recurrent hepatocellular carcinoma. Biotherapy 2007; 21:197-205.
29. Murata Y, Shimamura T, Tagami T, Takatsuki F, Hamuro J: The skewing to Thi induced by lentinan is directed tbrough the distinctive cytokine production by macrophages with elevated intracellular glutathione content. hit Immunopharmacol 2002; 2:673-689.
30. Vetvicka V, Yvin JC: Effects of marine beta-1,3 glucan on immune reactions. Int Immunopharmacol 2004; 4:721-730.
31. Yoshino 5, Tabata T, Hazama 5, et al: Immunoregulatory effects of the antitumor polysaccharide lentinan on ThlfI'h2 balance in patients with digestive cancers. Anticancer Res 2000; 20:4707-4711.
32. Moehiki E, Ohno T, Kamiyama Y, et al: Phase 1111 study of 5-1 combined with paditaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 2006; 95:1642-1647.
33. Kawabata R, Fujiwara Y, Doki Y, et al: Phase 1111 Study of a Combination of 5-1 and Weekly Pacitaxel in Patients with Advanced or Recurrent Gastric Cancer. Oncology 2008; 72:219-225.
34. Hamuro J, Murata Y, Suzuki M, Takatsuki F, Suga T: The triggering and healing of tumor stromal inflammatory reactions regulated by oxidative and reductive macrophages. Gann Monograph Cancer Res 1999; 48:153- 164.
35. Wasser SP: Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. AppI Microbiol Biotechnol 2002; 60:258-274.